• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Israel (State of) Jan 05 Product Image

Israel (State of) Jan 05

  • ID: 2046238
  • January 2005
  • Region: Israel
  • Standard & Poors

An advanced, prosperous, and export-oriented economy. Commitment to renewed structural reform. Solid external finances. High government deficit and public debt burdens. A small, open economy, vulnerable to external shocks. The solid investment grade ratings on Israel reflect its advanced, prosperous, export-oriented economy with few balance-of-payments pressures, underpinned by structural reforms. These strengths are offset, however, by Israel's vulnerability to its complex geopolitical environment, and the comparatively weak financial position of its government. Growth prospects continue to improve, in response to the strengthening of external demand, and a sharp recovery in private consumption and investment. In 2005, per capita incomes are forecast to expand by almost 2% in real terms, lifting nominal per capita incomes to $17,440, which is 27% higher...

Companies mentioned in this report are:
- Israel (State of)

Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown

- Israel (State of)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.